Target
$102.36 → $102.22
Public companyResearch currentFresh
Zimmer Biomet
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Orthopedic moat is migrating from commoditizing Knees/Hips (-0.8% pricing) onto ROSA robotics + ZBEdge data + Monogram autonomous CVR — Tech & Data $199.4M/qtr (+21%) is only ~9% of $2.177B Q2 sales. Surgeon/instrument-tray switching cost is real but multi-vendor (Stryker Mako, SNN CORI, J&J VELYS). Healthspan Intervene, research_only, INTACT.
Catalysts
Zimmer Biomet Q2 2026 earnings; hip/knee implant volume recovery; ROSA surgical robotics system placements; digital surgery platform expansion
Invalidation
(1) ROSA/Tech & Data growth decelerates toward implant-base rates and -0.8% pricing dominates. (2) Stryker Mako or a new entrant wins autonomous-surgery; Monogram CVR milestones through 2030 miss. (3) R&D keeps falling (Q2 -7.5% YoY) while $7.07B net debt limits the robotics build. (4) Paragon 28 / Monogram integration fails and amortization ($654M/yr) eats FCF. Source: vault 2026-08-30 (8-K EX-99.1 + 10-Q CIK0001136869, 2026-08-05).
Latest change
· Target moved from $102.22 to $102.17.
Research history
See all ZBH changes Earlier changes
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
| Fund / investor | As of | Fund portfolio weight | Evidence |
|---|---|---|---|
| iShares U.S. Medical Devices ETF IHI | 2.46% | Source |
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
ins-$1.5M · 13F 13+/11-×0.0 · short↓0.2
Current snapshotNeutral — No significant X discussion found in the last 30 days. [X search Aug 2026]
Lower-confidence snapshotTarget price: $106.09
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Qualification barrier
- Toll Road Tier
- Strong proxy
Timestamped research update
Deep research update
1,039 words · Updated 30 Aug 2026 · 2 sources
- Net sales $2,177.0M (+4.8% reported, +4.7% cc, +4.0% organic cc); H1 $4,263.7M (+7.0%).
- Gross margin 70.8% (COGS ex-amort $635.5M); operating income $326.1M (15.0% margin); net earnings $198.3M (9.1% margin).
- Adjusted EPS $2.07 (flat YoY); GAAP diluted EPS $1.03 (+33.8%).
- R&D $104.8M (−7.5% YoY) — declining while "innovation cycle" is the stated strategy (disconfirming).
- Operating cash flow $447.9M; FCF $308.3M (Q2).
- FY2026 guidance raised: revenue +3.9%–4.9% (was +2.5%–4.5%); organic cc +2.25%–3.25%; adjusted EPS $8.47–$8.59 (was $8.40–$8.55).
- monetization model: One-time hardware sales of orthopedic implants/instruments, plus consumables (bone cement, disposables) and services (robotics, navigation, logistics/support); no subscription/SaaS. ZBH FY2024 10-K Item 1; URL [sec.gov ; accession UNKNOWN]
- revenue mix: Knees ~29%, Hips ~19%, S.E.T. ~25%, CMFT ~11%, Dental ~6%, Spine/Other ~10%; geography Americas ~61%, EMEA ~21%, Asia Pacific ~18%. [10-K Segment Note; same URL; accession UNKNOWN]
- who pays: Hospitals, ASCs, surgeons; GPOs negotiate; distributors in some markets. [10-K Item 1; same URL; accession UNKNOWN]
- margin_value_capture: Gross margin ~70%; GAAP operating margin ~15%; adjusted operating margin ~26–27%; value accrues in proprietary implants, instrument trays, surgeon switching costs, consumables/robotics attach. [10-K Item 7; same URL; accession UNKNOWN]
- customer classes: Health Systems & Providers (hospitals, ASCs, surgeons), distributors/GPOs. 10-K Item 1; URL [sec.gov ; accession UNKNOWN]
Zimmer Biomet's healthspan moat is migrating off the commoditizing metal implant (Knees/Hips) and onto the orthopedic "Technology & Data" layer — the ROSA® surgical-robotics platform plus the ZBEdge data/analytics stack and the newly-acquired Monogram semi/fully-autonomous robotics. The binding constraint is surgeon-and-hospital workflow lock-in: the physical implant is 90+ years old and price-deteriorating (−0.8% YoY pricing), while the robotics/data segment compounds at +21% — the irreplaceable friction is retraining + re-instrumentation + re-validation cost of switching a surgical robotics ecosystem, not the implant itself.
- ROSA® Robot + bone cement are the named drivers of the +21.1% "Technology & Data, Bone Cement and Surgical" segment growth (Q2 2026 10-Q MD&A, "primarily due to strong net sales of our ROSA Robot and bone cement products").
- Monogram Technologies acquisition (closed Oct 7, 2025): "semi- and fully-autonomous robotic technologies… enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively" (Q2 2026 10-Q). Deal structure = $4.04/share cash + a non-tradeable CVR worth up to $12.37/share contingent on product/regulatory/revenue milestones through 2030 — a milestone-gated bet on the autonomous-surgery moat.
- Paragon 28 (closed April 2025, foot & ankle): $1,276.5M consideration ($1,241.5M cash + $35.0M contingent), adding a differentiated S.E.T. sub-franchise with dedicated surgeon sub-specialization.
- Switching cost is operational: ROSA robotics locks instrument trays, surgeon preference cards, and the data/analytics workflow into ZBH's ecosystem; a hospital switching to Stryker Mako or Smith+Nephew CORI re-buys capital, re-trains surgeons, and re-runs the payor/provider workflow.
- product_service: Orthopedic reconstructive implants and surgical technologies (knees, hips, S.E.T., CMFT, dental, spine; ROSA robotics). 10-K Item 1; URL [sec.gov ; accession UNKNOWN]
- technical function: Replace/repair joints with biomechanical implants, fixation, and bearing surfaces; robotics/navigation assist precision and alignment. [10-K Item 1; same URL; accession UNKNOWN]
- why it is hard: Class II/III regulatory approvals, long clinical evidence, surgeon training, IP, scale manufacturing, sterile instrument logistics, hospital contracts, and switching costs. [10-K Item 1/Risk Factors; same URL; accession UNKNOWN]
- substitutes: Conservative/non-surgical care; generic/private-label implants; other ortho majors (Stryker, DePuy Synthes, Smith & Nephew, Medtronic); emerging robotics. [10-K Item 1; same URL; accession UNKNOWN]
- pricing power: MED — reimbursement pressure and GPO contracting offset by differentiated implants/robotics and switching costs. [10-K Item 1/7; same URL; accession UNKNOWN]
- Stryker (Mako) is the dominant orthopedic-robotics incumbent with the largest installed base; Smith+Nephew (CORI) and J&J DePuy Synthes (VELYS) compete directly.
- ZBH's differentiated angle is the Monogram autonomous-surgery roadmap (milestone-CVR) — an attempt to leapfrog from image-guided (Mako) to semi/fully autonomous, which would be a step-change in the robotics moat if milestones convert.
- No hyperscaler exposure (medtech — no cloud/GPU substitute for implants or surgical robotics). GLP-1 drugs (semaglutide/tirzepatide) are an indirect demand factor, not a substitute.
- R&D declining −7.5% YoY while the autonomous-robotics moat is the stated growth driver — the company is funding the moat via CVR-contingent M&A rather than internal R&D.
- GAAP vs adjusted EPS ~2× gap ($1.03 vs $2.07) and $654M/yr intangible amortization: earnings quality depends on add-backs; the moat is acquisition-built.
- −0.8% pricing on 90% of revenue: if the robotics/data layer stalls, the base is a commoditizing implant franchise with 3 major competitors.
- Net debt $7.07B (~3× annualized EBITDA) limits capital for the robotics/data buildout; interest expense is a structural drag.
- If Stryker Mako or a new entrant wins the autonomous-surgery race first, ZBH's Monogram CVR milestones ($12.37/share contingent) become the tell — failure to convert milestones by 2030 would falsify the robotics-moat thesis.
- 2026-08-05: Q2 FY2026 results + raised FY2026 guidance (revenue +3.9%–4.9%, adj EPS $8.47–$8.59).
- 2025-10-07: Monogram Technologies autonomous-robotics acquisition closed (CVR up to $12.37/share through 2030).
- 2025-04: Paragon 28 (foot & ankle) closed, $1.28B.
- 2026-08-05 8-K: Q2 10-Q filed (segment detail + goodwill reallocation to 5 reporting units).
- technical_scarcity: 5/10 — ROSA + Monogram autonomous robotics is a real switching-cost moat (surgeon training, instrument trays, 510(k) regulatory, data workflow), but it is only ~9% of revenue; the core implant is a 90-year commodity facing Stryker/Smith+Nephew/J&J. Cited: Tech & Data $199.4M = 9.2% of $2,177M (8-K EX-99.1).
- economic_capture: 4/10 — captures the robotics/data economics (+21% segment) but 90% of the base is commoditizing (−0.8% pricing); GAAP EPS $1.03 vs adjusted $2.07 (~2× gap) and $7.07B net debt dilute the capture. Cited: 10-Q MD&A + income statement.
- time_to_monetize: 6/10 — robotics/data already monetizing (+21% organic); aging demographics + GLP-1-driven surgical-eligibility expansion are 6–24-month demand tailwinds; Monogram autonomous milestones stretch to 2030. Cited: FY2026 guidance raised (8-K EX-99.1).
Primary and supporting material
Sources
2 sources preserved from the latest qualified research update.